Published in Clin Pharmacol Ther on February 10, 2017
Measuring the Value of Pharmacogenomics Evidence. Clin Pharmacol Ther (2017) 0.75
Apixaban versus warfarin in patients with atrial fibrillation. N Engl J Med (2011) 23.50
CPIC: Clinical Pharmacogenetics Implementation Consortium of the Pharmacogenomics Research Network. Clin Pharmacol Ther (2011) 10.95
A randomized trial of genotype-guided dosing of warfarin. N Engl J Med (2013) 7.18
A pharmacogenetic versus a clinical algorithm for warfarin dosing. N Engl J Med (2013) 7.09
A randomized trial of genotype-guided dosing of acenocoumarol and phenprocoumon. N Engl J Med (2013) 4.27
Preference-Based EQ-5D index scores for chronic conditions in the United States. Med Decis Making (2006) 3.62
CYP2C9 genotype-guided warfarin prescribing enhances the efficacy and safety of anticoagulation: a prospective randomized controlled study. Clin Pharmacol Ther (2007) 3.60
The evidence dilemma in genomic medicine. Health Aff (Millwood) (2008) 3.58
Genotype-guided vs clinical dosing of warfarin and its analogues: meta-analysis of randomized clinical trials. JAMA Intern Med (2014) 3.40
A randomized and clinical effectiveness trial comparing two pharmacogenetic algorithms and standard care for individualizing warfarin dosing (CoumaGen-II). Circulation (2012) 3.30
A rational framework for decision making by the National Institute For Clinical Excellence (NICE). Lancet (2002) 3.26
Clinical implementation of pharmacogenomics: overcoming genetic exceptionalism. Lancet Oncol (2010) 2.52
Methods for the estimation of the National Institute for Health and Care Excellence cost-effectiveness threshold. Health Technol Assess (2015) 2.26
A policy model to evaluate the benefits, risks and costs of warfarin pharmacogenomic testing. Pharmacoeconomics (2010) 2.19
A randomized controlled trial of genotype-based Coumadin initiation. Genet Med (2011) 2.13
A prospective, randomized pilot trial of model-based warfarin dose initiation using CYP2C9 genotype and clinical data. Clin Med Res (2005) 2.05
Expected value of sample information calculations in medical decision modeling. Med Decis Making (2004) 2.04
Utilization of acute care services in the year before and after first stroke: A population-based study. Neurology (1996) 1.77
Model parameter estimation and uncertainty: a report of the ISPOR-SMDM Modeling Good Research Practices Task Force--6. Value Health (2012) 1.76
Value-of-information analysis within a stakeholder-driven research prioritization process in a US setting: an application in cancer genomics. Med Decis Making (2013) 1.70
Administrative claims analysis of the relationship between warfarin use and risk of hemorrhage including drug-drug and drug-disease interactions. J Manag Care Pharm (2006) 1.63
ACC/AHA statement on cost/value methodology in clinical practice guidelines and performance measures: a report of the American College of Cardiology/American Heart Association Task Force on Performance Measures and Task Force on Practice Guidelines. J Am Coll Cardiol (2014) 1.58
Evidence for Clinical Implementation of Pharmacogenomics in Cardiac Drugs. Mayo Clin Proc (2015) 1.51
Amiodarone, anticoagulation, and clinical events in patients with atrial fibrillation: insights from the ARISTOTLE trial. J Am Coll Cardiol (2014) 1.45
Dealing with the evidence dilemma in genomics and personalized medicine. Clin Pharmacol Ther (2010) 1.43
Validation of VKORC1 and CYP2C9 genotypes on interindividual warfarin maintenance dose: a prospective study in Chinese patients. Pharmacogenet Genomics (2009) 1.41
Antithrombotic and thrombolytic therapy: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). Chest (2008) 1.41
The value of implementation and the value of information: combined and uneven development. Med Decis Making (2008) 1.25
A critical analysis of barriers to the clinical implementation of pharmacogenomics. Ther Clin Risk Manag (2007) 1.18
Scientific challenges and implementation barriers to translation of pharmacogenomics in clinical practice. ISRN Pharmacol (2013) 0.98
Pharmacogenetic tests: the need for a level playing field. Nat Rev Drug Discov (2013) 0.92
Mechanism of warfarin potentiation by amiodarone: dose--and concentration--dependent inhibition of warfarin elimination. Eur J Clin Pharmacol (1985) 0.92
Value of information analyses of economic randomized controlled trials: the treatment of intermittent claudication. Value Health (2009) 0.89
Major bleeding risk associated with warfarin and co-medications in the elderly population. Pharmacoepidemiol Drug Saf (2011) 0.88
Impact of genotype-guided dosing on anticoagulation visits for adults starting warfarin: a randomized controlled trial. Pharmacogenomics (2013) 0.87
Prospective pilot trial of PerMIT versus standard anticoagulation service management of patients initiating oral anticoagulation. Thromb Haemost (2012) 0.85
Development and Evaluation of an Approach to Using Value of Information Analyses for Real-Time Prioritization Decisions Within SWOG, a Large Cancer Clinical Trials Cooperative Group. Med Decis Making (2016) 0.82
Pharmacogenetics-Based versus Conventional Dosing of Warfarin: A Meta-Analysis of Randomized Controlled Trials. PLoS One (2015) 0.81
How to estimate the health benefits of additional research and changing clinical practice. BMJ (2015) 0.76
Hospitalization for hemorrhage among warfarin recipients prescribed amiodarone. Am J Cardiol (2013) 0.76